Mobile Addiction Clinics Reached 4,645 People in Massachusetts

Medication-assisted treatment reached 4,645 people across Massachusetts over two and a half years, delivered from vans parked on ordinary streets rather than from clinics.

A new four-year analysis of the state’s mobile addiction programs puts numbers on how many people that model has helped, and the researchers behind it say the reach can grow.

The study was co-led by investigators at Mass General Brigham and published in the International Journal of Environmental Research and Public Health.

Who the Programs Reached

The 4,645 figure matters because of who it counts. The program, Community Care in Reach, was built by Mass General Brigham’s Kraft Center for Community Health specifically for people at high risk of drug-related illness and death who are unhoused or at risk of losing housing, and who were largely disconnected from traditional addiction treatment.

These are the patients treatment systems most often miss. The researchers note that the six programs encountered various challenges as they scaled, and that every one of them still succeeded in engaging people the conventional system had not reached.

What Those People Received

Researchers examined January 1, 2022 through June 30, 2024. In that window the programs logged 16,117 clinical encounters serving those 4,645 individuals.

Separately, teams recorded 17,887 harm reduction encounters, aimed at reducing the health, social, and legal consequences tied to drug use. That is a second, larger stream of contact running alongside the clinical care.

Buprenorphine was started in 1,227 people. Of those, 15 percent were still in buprenorphine-based treatment 180 days later.

Why the Number Is Likely to Keep Rising

The program began as a single vehicle in Boston in 2018. It now operates as six programs statewide, supported by the Massachusetts Department of Public Health and the Kraft Center, with five vans donated by the Kraft family and operations funded through the state Bureau of Substance Addiction Services and a SAMHSA grant.

The expansion held up because the model did not depend on who was running it. Programs were operated by organizations ranging from academic medical systems to community health centers, and senior author Elsie M. Taveras, MD, MPH, of Mass General Brigham and the Kraft Center described the model as highly adaptable across different regions.

A program that only works inside a major academic hospital cannot travel. This one did. Cynthia A. Tschampl, PhD, a senior research scientist at Brandeis University’s Heller School, said the findings show the model “can be expanded to reach and serve adults with very complex needs,” and that the physical presence of the units offers a popular, low-barrier way in.

Understanding Buprenorphine

Buprenorphine is an FDA-approved medication for opioid use disorder. It is a partial opioid agonist, meaning it occupies the same brain receptors that heroin, fentanyl, and prescription opioids act on but activates them only partially. That is what lets it reduce withdrawal symptoms and cravings without producing the same intensity of effect.

Timing matters at the start. Beginning buprenorphine while a full opioid agonist is still active can trigger precipitated withdrawal, which comes on abruptly and is severe. Induction is therefore done with clinical guidance, which a staffed mobile unit can provide on the spot.

Finding Medical Detox and Medication-Assisted Treatment

Where care physically shows up changes who receives it. Questions worth asking directly:

• Does a mobile unit or outreach team operate in your area
• Does the program offer buprenorphine, methadone, or naltrexone, and is induction supervised
• What happens after the first prescription, and who manages the medication long term
• Is telehealth available if getting to a clinic is the obstacle

Detox.com can help connect people with medically supervised detox and medication-assisted treatment providers, including programs that continue medication after the initial detox period. Call 800-996-6135(Sponsored) to speak with a treatment advisor today.